Sponsor The Eve Research Project
Closing the Data Gap, One Woman at a Time
Most research isolates hormones, immune disease, medication response, and environmental exposure. The Eve Research Project connects them into a single real world intelligence system.
Phase 1 launch begins July 8th, 2026. This is where early signals become usable intelligence for research, care, and next generation therapeutics.
The System Is Missing the Connection
Autoimmune disease is not experienced in isolated systems, but it is still studied that way.
What Becomes Possible With Your Sponsorship
The Eve Research Project turns real-world health signals into structured, usable intelligence.
Your sponsorship helps launch Phase 1 of the Eve Research Project on July 8th, 2026. We have a baseline funding need of $13,500 to move from early patient informed insight into a structured research pilot. Support makes it possible to onboard participants, deliver the June 10th Invisible Trigger educational session, fund a minimum 30 day tracking sprint through Journal My Health, generate provider ready AI reports, and collect structured data across hormones, symptoms, medication response, environmental exposure, and flare behavior.
This work is designed to do more than document symptoms. Eve creates a structured data layer that can help identify flare patterns, treatment response shifts, environmental drivers, and early signs of system instability. These data are designed to integrate into DAWN™, CYNAERA’s broader immune, hormonal, and environmental terrain model, strengthening future research, trial design, predictive modeling, and earlier diagnostic conversations.
Our 30 Day Sprint Expected Impacts
Earlier Detection
Identifying system instability and disease progression before clinical thresholds are reached, enabling intervention at earlier and more treatable stages.
Precision Treatment
Aligning therapies with hormonal phase, immune state, and environmental conditions to reduce variability in response and improve patient outcomes.
Advanced Trial Design
Informing study design with longitudinal, multi-domain data that reflects how disease behaves outside controlled environments.
Scalable Infrastructure
Establishing a reusable data layer that can support research, clinical systems, and therapeutic development across autoimmune and related conditions.
Eve Study Design and Methodology Overview
Eve focuses on individuals experiencing autoimmune disease, suspected autoimmune disease, infection associated chronic conditions, and related symptom clusters across hormonal transitions, with an emphasis on perimenopause, menopause, and post menopause. The phase 1 launch of the Eve Research Project begins on July 8th, 2026. The study prioritizes people who are often underrepresented in clinical research, including those with complex illness presentations, delayed diagnosis, uncertain diagnosis, or persistent symptoms that have not been clearly explained.
Participants are recruited through trusted community outreach, digital platforms, advocacy networks, and partner channels. This approach helps reach populations often missed by traditional studies because of diagnostic uncertainty, access barriers, geography, medical dismissal, or lack of specialty care. The goal is to build a research cohort that reflects the real conditions in which autoimmune and chronic illness are experienced, tracked, and managed.
Phase 1 Pilot Design
-
Cohort onboarding and baseline data capture
-
30 day longitudinal symptom and exposure tracking
-
Early-stage pattern detection and signal validation
-
Integration of hormonal stage, medication use, and environmental inputs
Key Milestones
14
MINIMUM DAYS THRESHOLD
200+
MEDICATIONS ANALYZED
672+
50K+
PREDICTION HOUR RANGE
DATA POINTS ANALYZED
Why The Eve Research Project Is Different
Most autoimmune research is built on static, single variable models that fail to capture how disease actually behaves. Hormones, immune activity, treatment response, and environmental exposure are studied in isolation, leaving the interactions that drive flare severity, treatment variability, and disease progression largely unmeasured. Eve is designed to capture those interactions directly. By generating high frequency, within patient data across hormonal transitions, immune activity, medication response, environmental exposure, and symptom dynamics, it produces a level of resolution that is not available in traditional clinical datasets or trial environments.
This creates a new class of data asset: one that can identify early instability signals, reveal treatment response patterns, and map escalation pathways before clinical deterioration occurs. It enables more precise stratification, more adaptive trial design, and a clearer understanding of how disease evolves across hormonal life stages. Integrated into the DAWN™ framework, Eve contributes patient level trajectory data to a broader system that models immune, hormonal, and environmental interactions at scale. The result is not just a study, but a foundation for a new research and intelligence layer capable of informing clinical strategy, therapeutic development, and long term system level decision making.
The Eve Research Project Team
The Eve Research Project is led by Cynthia Adinig, Tracey Welson Rossman, and Jamie Nicole. Together, we bring experience across health policy, research, technology, and community care to better understand how hormonal transitions shape autoimmune disease and chronic illness. Our work is grounded in both professional expertise and personal experience. We have seen how gaps in data and care leave women without answers, especially during midlife changes like perimenopause and menopause. We also understand this firsthand as women navigating complex health conditions in systems that often fail to recognize these shifts.
The Eve Research Project , launching phase on July 8th, 2026, is our response. It is an AI powered, patient centered research initiative designed to capture patterns across immune activity, hormonal changes, and treatment response. By combining lived experience with structured data, we aim to identify what traditional research has missed and translate those insights into clearer understanding, better care, and more informed decision making.
About Cynthia Adinig
About Me
A national health policy advisor, researcher, and Long COVID advocate, Cynthia has been featured in TIME, The Washington Post, Bloomberg, USA Today, and more. She serves on federal health committees, advises major research institutions, and is the founder of CYNAERA, and Co-Founder of BIPOC Equity Agency. She builds environment and relational justice aware AI tools to repair broken systems, including healthcare. Cynthia is also a patient, mother, and survivor of diagnostic failure who has spent years turning lived experience into structural change.
About Tracey Welson-Rossman
About Me
Tracey is a decades long entrepreneur in health innovation. As the founder of Journal My Health, a platform, she helps patients track complex symptoms and connect with their care teams. She is also a nationally recognized speaker on women in tech, founder of TechGirlz, and a trusted voice on health and patient-centered design. Tracey brings decades of product strategy and community building, along with her own journey and as a caregiver, navigating midlife health in a fragmented system.
About Jamie Nicole
About Me
Jamie Nicole is a certified Holistic Health Coach and Autoimmune Strategist with over twenty years of experience in health and wellness. As the founder of The Natural HEALing Coach and the AIP BIPOC Network, she has worked closely within the community to support women from adulthood through older age as they navigate autoimmune disease, chronic symptoms, and the challenges of sustainable lifestyle change. Shaped by her own personal health journey, Jamie has built a trusted platform centered on education, empowerment, and restoration.
Why We Are Care About Autoimmune Illness and Menopause
Over 11 million women in the U.S. are living at the intersection of autoimmunity and menopause. Many of them have spent years, even decades, managing complex conditions like lupus, multiple sclerosis, Hashimoto’s, rheumatoid arthritis, psoriasis, IBD, and more. As they enter perimenopause or post menopause, their symptoms often intensify or change in unfamiliar ways. Medications that once helped stop working. New sensitivities emerge. Flares last longer and hit harder. Yet not a single one of the top 50 chronic illness drugs we reviewed included full menopause-stage safety testing. Most don’t track hormone phase or separate outcomes by life stage. Women in midlife are being prescribed treatments that were never tested for their current biology.
This is not just a research oversight. It’s a longstanding issue that affects care, outcomes, and quality of life. It costs the U.S. an estimated $75–80 billion a year in avoidable healthcare costs, lost productivity, and long-term disability. But those numbers don’t speak to the emotional cost. The frustration of not being believed. The fear of getting worse with no answers. The pressure to keep going while feeling your body slip out from under you. We’re not outsiders to this experience. We are women who have navigating it firsthand, and who have also worked across healthcare, policy, and technology at the highest levels.
We carry both the personal insight and the professional tools to reimagine what’s possible. Our work is rooted in deep respect for the women who entrust us with their stories. In a time where more women are rightfully questioning how their reproductive and hormonal data is used, we want to be clear. We do not release identities to corporations, government agencies, or research institutions. Every insight we build is only to inform better care, never to exploit your trust. The Eve Research Project is not just another AI project. We are reclaiming this missing chapter in women’s health with data, with care, and with the community it should have always had. To the women quietly managing flares, brain fog, bone-deep fatigue, and hormonal shifts that seem to change everything overnight, we see you. You are not invisible, and you are not alone. You are the reason we created The Eve Research Project.
The Invisible Trigger: Why Menopause Resets the Rule Panel
In a live panel, June 10th at 1pm EST , The Invisible Trigger: Why Menopause Resets the Rules, we’ll explore how hormonal transitions reshape immune behavior, symptom patterns, and medication effectiveness, often in ways that go unrecognized. This conversation brings together the Eve Research Project team alongside a growing group of expert guests across clinical care, research, and patient advocacy who are helping to surface and validate these patterns in real time. Together, we will examine what is being missed, why it matters, and how these insights can begin to reshape both care and research. This session is designed to be immediately useful, offering practical insights, real world pattern recognition, and a downloadable Doctor’s Checklist to help guide more informed conversations and next steps.
Partner With Our Innovative Team
The Eve Research Project is open to researchers, clinicians, institutions, and industry partners interested in autoimmune disease, menopause, patient centered outcomes, and real world evidence. Independent, academic, NIH, and PCORI aligned collaborators can help shape study design, analysis, and representative research models. Clinical and translational researchers can explore within patient trajectories across hormonal stage, medication response, environmental exposure, and flare behavior. Therapeutics and digital health partners can use Eve’s structured data layer to better understand treatment variability, subgroup patterns, and trial design opportunities.
All collaboration is grounded in patient trust, ethical data use, and integration into DAWN™, CYNAERA’s broader immune, hormonal, and environmental terrain model. Researchers and partners interested in early collaboration are invited to connect.
Bioadaptive Systems Therapeutics™ (BST) and affiliated frameworks are proprietary systems by Cynthia Adinig, licensed exclusively to CYNAERA™ for commercialization and research integration. U.S. Provisional Patent Application No. 63/909,951 – Patent Pending. All rights reserved. CYNAERA is a Virginia, USA - based LLC registered in Montana